Clinical trial · Observational
Seroma and Hematoma Rates: MAXIGESIC IV vs. Ketorolac in Breast Cancer Surgery
Comparative Analysis of Seroma and Hematoma Rates: MAXIGESIC vs. Ketorolac in Breast Cancer Surgery Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators aim to compare the incidence rates of seroma (fluid collection) and hematoma (blood clot) following breast cancer surgery between the conventional non-steroidal anti-inflammatory drug (NSAID) Ketorolac and MAXIGESIC. The investigators seek to determine the complication rates in patients receiving MAXIGESIC post-surgery, hypothesizing that the higher dosage of ibuprofen in MAXIGESIC compared to Ketorolac will result in lower complication rates.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Post-Op Complication | — | UNRESOLVED | — |
| Post-Operative Hematoma | — | UNRESOLVED | — |
| Seroma as Procedural Complication | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- MAXIGESIC
- description
- Maxigesig group
- label
- Ketololac
- description
- ketololac group
Primary outcomes (3)
- measure
- Postoperative hemovac or JP total drainage amount
- timeFrame
- within 3 months
- description
- Postoperative hemovac or JP total drainage amount
- measure
- hematoma incidence
- timeFrame
- within 3 months
- description
- hematoma incidence
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Systemic performance status 0-2 according to ECOG criteria * Patients with adequate renal function: serum Cr 1.4 mg/dL or less * Patients with adequate liver function Bilirubin, AST/ALT: 1.5 times or less of the upper limit of normal, Alkaline phosphatase: 1.8 times or less of the upper limit of normal * Patients undergoing total mastectomy with SLNB or ALND (mastectomy and axillary sentinel lymph node dissection) * Patients undergoing breast-conserving surgery with ALND (mastectomy and axillary dissection) * Patients who voluntarily decided to participate in this study and signed a written informed consent form Exclusion Criteria: * Patients undergoing immediate reconstruction operation * Patients with drug allergies to painkillers and anti-inflammatory drugs * Patients with a physical condition that would interfere with understanding and submitting the consent form
References
Publications (0)
Data not yet available